The weight-loss drug opportunity could approach $100 billion by the end of the decade.Eli Lilly (LLY 0.15%) stock has soared in the triple digits over the past three years thanks to one particular product line: its weight-loss drugs. Lilly is the maker of tirzepatide, sold under the name Mounjaro for type 2 diabetes and Zepbound for weight loss. But physicians have prescribed either for patients aiming to control their weight.These two drugs have become blockbusters, generating billions of dollars for the c ...